Gridai Technologies Corp (GRDX)

$2.55 -0.08 (-3.04%)
Market Cap 8.84M
Revenue (ttm) 0.00
Net Income (ttm) -18.06M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.01
Volume 14,000
Avg Vol 111,124
Day's Range N/A - N/A
Shares Out 3.36M
Stochastic %K 50%
Beta 1.14
Analysts Hold
Price Target N/A

Company Profile

GridAI Technologies Corp. designs and develops an artificial intelligence (AI)-driven software and device platform that enables utilities, retailers, and large power users to manage load and distributed energy resources. The company's Aggregation Management Platform leverages IoT, AI/ML, and edge analytics to forecast, optimize, and dispatch flexible demand. The company also engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastroin...

Industry: Biotechnology
Sector: Healthcare
Address:
91 George St, Edinburgh, United Kingdom
Latest News on GRDX
Entero Therapeutics, Inc. Announces Corporate Name Change to GridAI Technologies Corp. and New Ticker Symbol "GRDX"

Nov 28, 2025, 8:00 AM EST - 27 days ago

Entero Therapeutics, Inc. Announces Corporate Name Change to GridAI Technologies Corp. and New Ticker Symbol "GRDX"

ENTO Subsidiary Grid AI Announces Letter of Intent with First Hyperscaler AI Data-Center Customer

Nov 19, 2025, 8:45 AM EST - 5 weeks ago

ENTO Subsidiary Grid AI Announces Letter of Intent with First Hyperscaler AI Data-Center Customer

Entero's Grid AI Prepares for Major U.S. Expansion with New Leadership Appointments to Accelerate AI Infrastructure Strategy

Nov 13, 2025, 8:35 AM EST - 6 weeks ago

Entero's Grid AI Prepares for Major U.S. Expansion with New Leadership Appointments to Accelerate AI Infrastructure Strategy

Entero Subsidiary Grid AI Accelerates Expansion into Hyperscaler AI Data Center Market with Integration of LV Grid

Nov 6, 2025, 8:45 AM EST - 7 weeks ago

Entero Subsidiary Grid AI Accelerates Expansion into Hyperscaler AI Data Center Market with Integration of LV Grid

Entero's Reinvention Gives the Grid, AI, and Investors Exactly What They're After: Power and Value (NASDAQ: ENTO)

Oct 30, 2025, 9:00 AM EDT - 2 months ago

Entero's Reinvention Gives the Grid, AI, and Investors Exactly What They're After: Power and Value (NASDAQ: ENTO)

Entero Regains Nasdaq Compliance With Grid AI Acquisition

Oct 30, 2025, 6:00 AM EDT - 2 months ago

Entero Regains Nasdaq Compliance With Grid AI Acquisition

Entero Therapeutics, Inc., Launches Grid AI Corp to Redefine How AI Infrastructure Connects to the Power Grid

Oct 16, 2025, 8:40 AM EDT - 2 months ago

Entero Therapeutics, Inc., Launches Grid AI Corp to Redefine How AI Infrastructure Connects to the Power Grid

From Biotech to Grid Tech, Entero Therapeutics Enters a $2.5 Billion Market Expected to Quadruple by 2033 (NASDAQ:ENTO)

Oct 14, 2025, 11:00 AM EDT - 2 months ago

From Biotech to Grid Tech, Entero Therapeutics Enters a $2.5 Billion Market Expected to Quadruple by 2033 (NASDAQ:ENTO)

Entero Therapeutics Steps Into the $2.5 Billion Grid-Edge Arena With Global-Scale Validation Behind It

Oct 14, 2025, 8:00 AM EDT - 2 months ago

Entero Therapeutics Steps Into the $2.5 Billion Grid-Edge Arena With Global-Scale Validation Behind It

Stock Market Today: Dow Futures Slip, Nasdaq Rises Amid Mixed Trade—AngioDynamics, Entero Therapeutics, Fermi In Focus

Oct 2, 2025, 5:50 AM EDT - 3 months ago

Stock Market Today: Dow Futures Slip, Nasdaq Rises Amid Mixed Trade—AngioDynamics, Entero Therapeutics, Fermi In Focus

FRMI

ENTERO THERAPEUTICS (ENTO) Enters $100 Billion+ AI and Data Center Market with Acquisition of GRID AI

Oct 1, 2025, 4:05 PM EDT - 3 months ago

ENTERO THERAPEUTICS (ENTO) Enters $100 Billion+ AI and Data Center Market with Acquisition of GRID AI

ENTERO THERAPEUTICS (ENTO) Acquires 100% of GRID AI, a Grid-Edge AI Platform Optimizing Next-Gen Power Demand

Oct 1, 2025, 8:30 AM EDT - 3 months ago

ENTERO THERAPEUTICS (ENTO) Acquires 100% of GRID AI, a Grid-Edge AI Platform Optimizing Next-Gen Power Demand

Entero Therapeutics, Inc. Announces Reverse Stock Split

Aug 14, 2025, 9:15 AM EDT - 4 months ago

Entero Therapeutics, Inc. Announces Reverse Stock Split

Entero Therapeutics, Inc. Announces $3.0 Million Private Placement Priced at the Market Under Nasdaq Rules

Aug 11, 2025, 7:30 AM EDT - 4 months ago

Entero Therapeutics, Inc. Announces $3.0 Million Private Placement Priced at the Market Under Nasdaq Rules

FluroTech Ltd. Announces Change in Directors

Jun 13, 2025, 10:46 AM EDT - 6 months ago

FluroTech Ltd. Announces Change in Directors

MMA

Entero Therapeutics Announces Signing of Rescission Agreement with ImmunogenX, LLC

Mar 24, 2025, 10:51 PM EDT - 9 months ago

Entero Therapeutics Announces Signing of Rescission Agreement with ImmunogenX, LLC

Entero Therapeutics Appoints Richard Paolone as CEO

Feb 14, 2025, 4:00 PM EST - 11 months ago

Entero Therapeutics Appoints Richard Paolone as CEO

Entero Therapeutics Secures $2 Million Revolving Loan; Appoints Three New Board Members

Feb 7, 2025, 3:22 PM EST - 11 months ago

Entero Therapeutics Secures $2 Million Revolving Loan; Appoints Three New Board Members

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders

Nov 15, 2024, 8:00 AM EST - 1 year ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders

PULM

ENTERO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Entero Therapeutics, Inc. - ENTO

Nov 14, 2024, 6:50 PM EST - 1 year ago

ENTERO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Entero Therapeutics, Inc. - ENTO

Entero Therapeutics Announces Proposed Reverse Merger with Journey Therapeutics, A Clinical Stage, First-in-Class, Next-Generation ADC-rivalling Nano-immunoconjugates Biopharmaceutical Company

Nov 13, 2024, 7:00 AM EST - 1 year ago

Entero Therapeutics Announces Proposed Reverse Merger with Journey Therapeutics, A Clinical Stage, First-in-Class, Next-Generation ADC-rivalling Nano-immunoconjugates Biopharmaceutical Company

Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

Oct 8, 2024, 5:00 AM EDT - 1 year ago

Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

OCS ONCO VRNA

Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q

Aug 23, 2024, 5:00 PM EDT - 1 year ago

Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q

Entero Therapeutics' Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program

Jul 31, 2024, 7:00 AM EDT - 1 year ago

Entero Therapeutics' Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program

Entero Therapeutics Announces Peer-Reviewed Publication Unveiling Novel Algorithm for Measuring Intestinal Damage in Celiac Disease

Jun 27, 2024, 6:00 AM EDT - 1 year ago

Entero Therapeutics Announces Peer-Reviewed Publication Unveiling Novel Algorithm for Measuring Intestinal Damage in Celiac Disease

Entero Therapeutics to Present Corporate Update at 2024 BIO International Convention

May 22, 2024, 7:00 AM EDT - 1 year ago

Entero Therapeutics to Present Corporate Update at 2024 BIO International Convention

Entero Therapeutics Presents Two Posters on Celiac Disease Research at the 2024 Digestive Disease Week (DDW) Conference

May 20, 2024, 7:00 AM EDT - 1 year ago

Entero Therapeutics Presents Two Posters on Celiac Disease Research at the 2024 Digestive Disease Week (DDW) Conference